search

Active clinical trials for "Choroidal Neovascularization"

Results 71-80 of 174

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization...

Pathological Myopia

This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).

Completed9 enrollment criteria

VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)

MyopiaPathological

VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial. 3 out of 4 patients will receive an injection of VEGF Trap-Eye into the affected eye (and repeated injections if required), and 1 out of 4 patients will receive a sham injection requiring no needle stick, but making the patient unaware of whether or not he received active treatment. Outcome of the two treatment groups will be compared after 24 weeks. From week 24, sham patients may receive active treatment. Total duration of the study will be 48 weeks.

Completed43 enrollment criteria

A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due...

Neovascular Age-related Macular Degeneration

This study is designed to assess the efficacy and safety of multiple intravitreal injection of KH902 in patients with CNV due to AMD.

Completed18 enrollment criteria

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Exudative Age-related Macular Degeneration

The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD). iSONEP not only has an anti-permeability effect, but also has anti-angiogenic, anti-inflammatory, and anti-fibrotic properties. The drug may therefore have the ability to achieve better visual outcomes than Lucentis, Avastin or Eylea, particularly in those subjects who do not demonstrate a robust response to Lucentis, Avastin or Eylea after several monthly injections. Further, the combination of Lucentis, Avastin or Eylea and iSONEP may be additive or synergistic. By inhibiting the multiple mechanisms that contribute to exudative-AMD-related vision loss, better visual outcomes may be possible than with Lucentis, Avastin or Eylea alone.

Completed28 enrollment criteria

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due...

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)

Completed8 enrollment criteria

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Retinal Pigment Epithelial Detachment

This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.

Completed33 enrollment criteria

Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes...

MyopiaChoroidal Neovascularization

The purpose of this study is to determine the efficacy and safety of intravitreal injections of bevacizumab in High Myopia´s choroidal neovascularization versus the standard treatment of Photodynamic therapy.

Completed15 enrollment criteria

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Age Related Macular DegenerationChoroidal Neovascularization1 more

To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.

Completed24 enrollment criteria

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655...

Age Related Macular Degeneration

The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.

Completed15 enrollment criteria

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

Age-related Macular Degeneration

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD

Completed12 enrollment criteria
1...789...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs